Servicio de Endocrinología y Nutrición, Clínica Rotger , Palma, Islas Baleares, España; Servicio de Endocrinología y Nutrición, Hospital Universitario Son Llàtzer, Palma, Islas Baleares, España; Instituto de Investigación de Baleares (IdISBa), Palma, Islas Baleares, España.
Servicio de Endocrinología y Nutrición, Clínica Rotger , Palma, Islas Baleares, España; Servicio de Endocrinología y Nutrición, Hospital Universitario Son Llàtzer, Palma, Islas Baleares, España; Instituto de Investigación de Baleares (IdISBa), Palma, Islas Baleares, España.
Med Clin (Barc). 2022 Feb 11;158(3):105-110. doi: 10.1016/j.medcli.2020.12.039. Epub 2021 Mar 26.
One of the potential negative effects of a lockdown are changes in dietary and lifestyle patterns, which can lead to weight gain. Our objective was to assess the changes on dietary habits and eating patterns in a lockdown situation and their impact on weight. We aimed to determine whether the treatment with GLP1 analogues (aGLP1) could impact on these parameters.
100 overweight/obese patients were consecutively recruited for a review at the end of the lockdown. A structured interview was designed to see changes in dietary habits, routines and exercise.
52% patients gained weight during lockdown. The percentage of subjects with an active history of depression or anxiety was higher among the group of patients who gained weight. The percentage of patients who worsened their hyperphagia was higher in those who gained weight (71.2% vs. 10.6%; P<0.0001); similar results were observed with binge eating (92% vs. 10.6%; p<0.0001) and cravings, both sweet and salty (69.2% vs. 21.3% and 69.2% vs. 14.9%; p<0.0001 and p<0.0001 respectively). Of the 48 patients who did not gain weight, 30 were under aGLP1 treatment (61.7%). The worsening of abnormal eating patterns was lower among patients treated with aGLP-1.
A lockdown is a vulnerable period to gain weight, especially in those patients with a psychopathological history. aGLP1 manage to control emotional eating, making them a valuable therapeutic option.
封锁可能带来的潜在负面影响之一是饮食和生活方式的改变，这可能导致体重增加。我们的目的是评估封锁期间饮食习惯和饮食模式的变化及其对体重的影响。我们旨在确定 GLP1 类似物（aGLP1）治疗是否会对这些参数产生影响。
连续招募了 100 名超重/肥胖患者在封锁结束后进行回顾。设计了一个结构化访谈，以了解饮食习惯、日常生活和运动的变化。
52%的患者在封锁期间体重增加。在体重增加的患者中，有活跃的抑郁或焦虑病史的患者比例较高。体重增加的患者中，饮食过度恶化的比例较高（71.2% vs. 10.6%；P<0.0001）；同样的结果也观察到暴食（92% vs. 10.6%；p<0.0001）和渴望甜食和咸食（69.2% vs. 21.3%和 69.2% vs. 14.9%；p<0.0001 和 p<0.0001）。在没有体重增加的 48 名患者中，有 30 名正在接受 aGLP1 治疗（61.7%）。接受 aGLP-1 治疗的患者异常饮食模式恶化的情况较低。
封锁是体重增加的脆弱时期，尤其是对于有精神病史的患者。aGLP1 能够控制情绪化进食，是一种有价值的治疗选择。
